Related Experiment Video

Updated: Aug 23, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Low-molecular-weight heparins for the treatment of acute coronary syndromes

Graham C Wong1, Robert P Giugliano

  • 1Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

Seminars in Vascular Medicine
|June 17, 2004
PubMed

Insights

Low-molecular-weight heparins (LMWHs) offer advantages over unfractionated heparin (UFH) for acute coronary syndromes (ACS). Further research is needed to confirm LMWH efficacy and safety across all ACS types.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Low-molecular-weight heparins (LMWHs) present advantages compared to unfractionated heparin (UFH).
  • LMWHs are indicated for unstable angina/non-ST elevation myocardial infarction (UA/NSTEMI).

Purpose of the Study:

  • To evaluate the potential of LMWHs in ST-elevation myocardial infarction (STEMI) and percutaneous coronary intervention (PCI).
  • To assess the safety of LMWH when used with glycoprotein IIb/IIIa inhibitors.

Main Methods:

  • Review of existing clinical studies and evidence.
  • Analysis of safety and efficacy data for LMWH in various acute coronary syndrome (ACS) settings.

Main Results:

  • LMWHs demonstrate promise in STEMI and PCI settings.
  • Evidence suggests equivalent safety of LMWH with glycoprotein IIb/IIIa inhibitors.

Conclusions:

  • LMWHs show potential for broader application in ACS treatment.
  • Larger clinical studies are required to confirm LMWH safety and efficacy across the full spectrum of ACS.

More Related Videos

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...